Subscribe To
Olema oncology announces positive phase 2 monotherapy clinical study results for palazestrant
Across all 86 heavily pretreated patients, the median PFS was 4.6 months with a CBR of 40%; in patients with e...
October 22, 2023, 6:55 am
esr1 mutated metastatic breast cancer diagnostics market to hit us$ 185 million by 2033 and grow at a cagr of 11% during forecast | future market insights, inc.
The esr1-mutated metastatic breast cancer market is expected to surge in the coming years due to the ri...
June 5, 2023, 2:30 pm
Context therapeutics says clinical partner stemline therapeutics receives fda approval for orserdu to treat certain breast cancers
Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Me...
January 31, 2023, 8:33 am